Close Menu

Breaking News

An analysis using UK Biobank data indicates that the CCR5-Δ32 gene mutations He Jiankui reportedly attempted to introduce into human embryos may be deleterious.

Dubbed Automobi Molecular Diagnostics, the company will establish local manufacturing facilities and work to commercialize the Novodiag platform in China.

The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.

Last week, GenomeWeb's readers were most interested in a patent infringement lawsuit that BGI's instrument subsidiary MGI filed against Illumina.

According to Natantis, researchers will be able to use the device to extract cell-free nucleic acids from whole blood in 45 minutes.

Bruker signed a codevelopment and comarketing agreement with PreOmics for sample prep, and a partnership with Genedata for proteomics software.

PerkinElmer disclosed earlier this month in its Form 10Q filed with the US Securities and Exchange Commission that it paid $219.8 million for its acquisition of Cisbio Bioassays

The company drew $49 from the credit facility to repay an earlier outstanding loan and expects to draw another $27 million to, in part, pay for its acquisition of GenePOC.

Evercore analysts set a price target of $30.50 for the company and said they see opportunities in DNA synthesis, NGS tools, pharmaceuticals, and DNA data storage.

The firm plans to use proceeds to fund commercial activities related to its ClonoSeq assay, as well as research into drug discovery and its project to map TCR antigens.

The project, established by the National Cancer Center of Japan, screens target genes in lung cancer to advance the development of new drugs and diagnostics.

The Columbia Solid Tumor Panel, a custom NGS panel from Pillar Biosciences, will be used at CUMC's Laboratory of Personalized Genomic Medicine.

The deals with Covance, NeoGenomics Laboratories, and Navigate BioPharma Services aim to expand access to NanoString's PanCancer IO 360 Gene Expression Panel.

The studies, which used multi-omic approaches, are part of the integrative Human Microbiome Project (iHMP) — the second phase of the Human Microbiome Project.

Using CRISPR mouse and iPS cell models, the researchers showed that a rare maternally inherited variant is a genetic modifier of two paternally inherited variants.

Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.

The researchers' model indicates that numerous admixture events took place as pastoralism arose in sub-Saharan Africa.

The assay is for detecting varicella-zoster virus in cerebrospinal fluid and can be used with the firm's Liaison MDx instrument.

Caris will use its whole-transcriptome sequencing assay and Molecular Intelligence Trials service to identify patients for a phase II clinical trial.

This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.

The company is commercializing a method developed by researchers at Johns Hopkins that detects cancer with high specificity from a blood sample.

Dutch researchers have cataloged genome-wide somatic mutations within fetal liver and intestine stem cells, finding different mutational patterns in those tissues.

Invitae will perform genetic testing using a 58-gene panel and Horizon will provide financial support for the program aimed at improving diagnosis of the rare condition.

Pages

Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.

An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.

Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.

In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.